Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Quantity of Toxin in Stool Correlates with C. difficile Severity

By LabMedica International staff writers
Posted on 25 Oct 2021
Clostridioides difficile (syn. Clostridium difficile), also known as C. More...
difficile, or C. diff are Gram-positive species of spore-forming bacteria. Clostridioides spp. are anaerobic, motile bacteria, ubiquitous in nature and especially prevalent in soil. C. difficile cells are Gram-positive and show optimum growth on blood agar at human body temperatures in the absence of oxygen.

Although C. difficile is commonly known as a hospital and antibiotic associated pathogen, at most one third of infections can be traced to transmission from an infected person in hospitals, and only a small number of antibiotics are directly associated with an elevated risk of developing a C. difficile infection (CDI). Pathogenic C. difficile strains produce multiple toxins.

Infectious Disease Specialists at the Beth Israel Deaconess Medical Center (Boston, MA, USA) and their colleagues enrolled 615 hospitalized adults (≥ 18 years) with CDI (acute diarrhea, positive stool Nucleic Acid Amplification Test (NAAT), and decision to treat). Baseline stool toxin A and B concentrations were measured by Simoa Single Molecule Array (Quanterix, Billerica, MA, USA). Subjects were classified by baseline CDI severity (four scoring methods) and outcomes within 40 days (death, ICU stay, colectomy, and recurrence).

The investigators reported that overall, the study showed that across all scoring systems, patients with severe baseline disease had higher stool toxin A and B concentrations than those without. Nineteen subjects (3.1%) had a severe outcome primarily-attributed to CDI (group 1). This group had higher median toxin A+B (14,303 pg/mL) than subjects in whom CDI only contributed to the outcome (group 2, 163.2 pg/mL), subjects with severe outcome unrelated to CDI (group 3, 158.6 pg/mL), or no severe outcome (group 4, 209.5 pg/mL). Group 1 was more likely to have detectable toxin (94.7%) than groups 2-4 (60.5%-66.1%). Individuals with recurrence had higher toxin A+B (2,266.8 pg/mL) than those without (154.0 pg/mL) and higher rates of detectable toxin (85.7% versus 64.0%).

Carolyn D. Alonso, MD, an Assistant Professor of Medicine and first author of the study, and her colleagues said, “This study lays the foundation for developing a highly accurate, single-step test to better diagnose C. difficile infection and predict clinical outcomes. Ultimately, we hope that our research will move the field toward development of a single-step test for C. difficile that can be easily deployed by clinicians without specific expertise in C. difficile diagnosis.”

The authors concluded that in CDI patients, ultrasensitive stool toxin detection and concentration correlated with severe baseline disease, severe CDI-attributable outcomes, and recurrence, confirming the contribution of toxin quantity to disease presentation and clinical course. The study was published on September 19, 2021 in the journal Clinical Infectious Diseases.

Related Links:
Beth Israel Deaconess Medical Center
Quanterix



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
Multichem ID-B
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.